How Does the Market View Moderna?

By Naomi Wentworth • Monday, December 11 16:42 • Permanent Link

Moderna stock is trading -32.42% below its average target price of $121.34 after marking a 2.1% during today's evening session. Analysts are giving the large-cap Biotechnology company an average rating of hold and target prices ranging from $48.26 to $278.43 per share.

Moderna has an average level of shares sold short, at 7.8% of its total share float. The stock's short ratio (also called days to cover) is 4.09. The company's insiders own 9.63% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Institutional investors own 69.2% of Moderna's shares, which indicates they have a high level of confidence in the company.

Institutions Invested in Moderna

Date Reported	Holder	Percentage	Shares	Value
2023-09-30	Baillie Gifford and Company	12%	45,649,183	$3,743,233,006
2023-09-30	Vanguard Group Inc	7%	27,658,449	$2,267,992,818
2023-09-30	Blackrock Inc.	6%	24,739,386	$2,028,629,652
2023-09-30	State Street Corporation	4%	13,951,276	$1,144,004,632
2023-09-30	Flagship Pioneering Inc.	3%	9,666,038	$792,615,116
2023-09-30	Theleme Partners LLP	2%	6,897,612	$565,604,184
2023-09-30	Geode Capital Management, LLC	2%	6,415,009	$526,030,738
2023-09-30	Wellington Management Group, LLP	1%	5,611,119	$460,111,758
2023-09-30	Morgan Stanley	1%	5,312,014	$435,585,148
2023-09-30	Coatue Management LLC	1%	4,909,578	$402,585,396

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.